Microfluidic-Enabled Print-to-Screen Platform for High-Throughput Screening of Combinatorial Chemotherapy

Yuzhe Ding, Jiannan Li, Wenwu Xiao, Kai Xiao, Joyce S Lee, Urvashi Bhardwaj, Zijie Zhu, Philip Digiglio, Gaomai Yang, Kit Lam, Tingrui Pan

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Since the 1960s, combination chemotherapy has been widely utilized as a standard method to treat cancer. However, because of the potentially enormous number of drug candidates and combinations, conventional identification methods of the effective drug combinations are usually associated with significantly high operational costs, low throughput screening, laborious and time-consuming procedures, and ethical concerns. In this paper, we present a low-cost, high-efficiency microfluidic print-to-screen (P2S) platform, which integrates combinatorial screening with biomolecular printing for high-throughput screening of anticancer drug combinations. This P2S platform provides several distinct advantages and features, including automatic combinatorial printing, high-throughput parallel drug screening, modular disposable cartridge, and biocompatibility, which can potentially speed up the entire discovery cycle of potent drug combinations. Microfluidic impact printing utilizing plug-and-play microfluidic cartridges is experimentally characterized with controllable droplet volume and accurate positioning. Furthermore, the combinatorial print-to-screen assay is demonstrated in a proof-of-concept biological experiment which can identify the positive hits among the entire drug combination library in a parallel and rapid manner. Overall, this microfluidic print-to-screen platform offers a simple, low-cost, high-efficiency solution for high-throughput large-scale combinatorial screening and can be applicable for various emerging applications in drug cocktail discovery.

Original languageEnglish (US)
Pages (from-to)10166-10171
Number of pages6
JournalAnalytical Chemistry
Volume87
Issue number20
DOIs
StatePublished - Sep 3 2015

Fingerprint

Chemotherapy
Microfluidics
Drug Combinations
Screening
Throughput
Printing
Costs
Biocompatibility
Pharmaceutical Preparations
Assays
Experiments

ASJC Scopus subject areas

  • Analytical Chemistry

Cite this

Microfluidic-Enabled Print-to-Screen Platform for High-Throughput Screening of Combinatorial Chemotherapy. / Ding, Yuzhe; Li, Jiannan; Xiao, Wenwu; Xiao, Kai; Lee, Joyce S; Bhardwaj, Urvashi; Zhu, Zijie; Digiglio, Philip; Yang, Gaomai; Lam, Kit; Pan, Tingrui.

In: Analytical Chemistry, Vol. 87, No. 20, 03.09.2015, p. 10166-10171.

Research output: Contribution to journalArticle

Ding, Y, Li, J, Xiao, W, Xiao, K, Lee, JS, Bhardwaj, U, Zhu, Z, Digiglio, P, Yang, G, Lam, K & Pan, T 2015, 'Microfluidic-Enabled Print-to-Screen Platform for High-Throughput Screening of Combinatorial Chemotherapy', Analytical Chemistry, vol. 87, no. 20, pp. 10166-10171. https://doi.org/10.1021/acs.analchem.5b00826
Ding, Yuzhe ; Li, Jiannan ; Xiao, Wenwu ; Xiao, Kai ; Lee, Joyce S ; Bhardwaj, Urvashi ; Zhu, Zijie ; Digiglio, Philip ; Yang, Gaomai ; Lam, Kit ; Pan, Tingrui. / Microfluidic-Enabled Print-to-Screen Platform for High-Throughput Screening of Combinatorial Chemotherapy. In: Analytical Chemistry. 2015 ; Vol. 87, No. 20. pp. 10166-10171.
@article{75770094e69d4a7a9e4ff9af5418c108,
title = "Microfluidic-Enabled Print-to-Screen Platform for High-Throughput Screening of Combinatorial Chemotherapy",
abstract = "Since the 1960s, combination chemotherapy has been widely utilized as a standard method to treat cancer. However, because of the potentially enormous number of drug candidates and combinations, conventional identification methods of the effective drug combinations are usually associated with significantly high operational costs, low throughput screening, laborious and time-consuming procedures, and ethical concerns. In this paper, we present a low-cost, high-efficiency microfluidic print-to-screen (P2S) platform, which integrates combinatorial screening with biomolecular printing for high-throughput screening of anticancer drug combinations. This P2S platform provides several distinct advantages and features, including automatic combinatorial printing, high-throughput parallel drug screening, modular disposable cartridge, and biocompatibility, which can potentially speed up the entire discovery cycle of potent drug combinations. Microfluidic impact printing utilizing plug-and-play microfluidic cartridges is experimentally characterized with controllable droplet volume and accurate positioning. Furthermore, the combinatorial print-to-screen assay is demonstrated in a proof-of-concept biological experiment which can identify the positive hits among the entire drug combination library in a parallel and rapid manner. Overall, this microfluidic print-to-screen platform offers a simple, low-cost, high-efficiency solution for high-throughput large-scale combinatorial screening and can be applicable for various emerging applications in drug cocktail discovery.",
author = "Yuzhe Ding and Jiannan Li and Wenwu Xiao and Kai Xiao and Lee, {Joyce S} and Urvashi Bhardwaj and Zijie Zhu and Philip Digiglio and Gaomai Yang and Kit Lam and Tingrui Pan",
year = "2015",
month = "9",
day = "3",
doi = "10.1021/acs.analchem.5b00826",
language = "English (US)",
volume = "87",
pages = "10166--10171",
journal = "Analytical Chemistry",
issn = "0003-2700",
publisher = "American Chemical Society",
number = "20",

}

TY - JOUR

T1 - Microfluidic-Enabled Print-to-Screen Platform for High-Throughput Screening of Combinatorial Chemotherapy

AU - Ding, Yuzhe

AU - Li, Jiannan

AU - Xiao, Wenwu

AU - Xiao, Kai

AU - Lee, Joyce S

AU - Bhardwaj, Urvashi

AU - Zhu, Zijie

AU - Digiglio, Philip

AU - Yang, Gaomai

AU - Lam, Kit

AU - Pan, Tingrui

PY - 2015/9/3

Y1 - 2015/9/3

N2 - Since the 1960s, combination chemotherapy has been widely utilized as a standard method to treat cancer. However, because of the potentially enormous number of drug candidates and combinations, conventional identification methods of the effective drug combinations are usually associated with significantly high operational costs, low throughput screening, laborious and time-consuming procedures, and ethical concerns. In this paper, we present a low-cost, high-efficiency microfluidic print-to-screen (P2S) platform, which integrates combinatorial screening with biomolecular printing for high-throughput screening of anticancer drug combinations. This P2S platform provides several distinct advantages and features, including automatic combinatorial printing, high-throughput parallel drug screening, modular disposable cartridge, and biocompatibility, which can potentially speed up the entire discovery cycle of potent drug combinations. Microfluidic impact printing utilizing plug-and-play microfluidic cartridges is experimentally characterized with controllable droplet volume and accurate positioning. Furthermore, the combinatorial print-to-screen assay is demonstrated in a proof-of-concept biological experiment which can identify the positive hits among the entire drug combination library in a parallel and rapid manner. Overall, this microfluidic print-to-screen platform offers a simple, low-cost, high-efficiency solution for high-throughput large-scale combinatorial screening and can be applicable for various emerging applications in drug cocktail discovery.

AB - Since the 1960s, combination chemotherapy has been widely utilized as a standard method to treat cancer. However, because of the potentially enormous number of drug candidates and combinations, conventional identification methods of the effective drug combinations are usually associated with significantly high operational costs, low throughput screening, laborious and time-consuming procedures, and ethical concerns. In this paper, we present a low-cost, high-efficiency microfluidic print-to-screen (P2S) platform, which integrates combinatorial screening with biomolecular printing for high-throughput screening of anticancer drug combinations. This P2S platform provides several distinct advantages and features, including automatic combinatorial printing, high-throughput parallel drug screening, modular disposable cartridge, and biocompatibility, which can potentially speed up the entire discovery cycle of potent drug combinations. Microfluidic impact printing utilizing plug-and-play microfluidic cartridges is experimentally characterized with controllable droplet volume and accurate positioning. Furthermore, the combinatorial print-to-screen assay is demonstrated in a proof-of-concept biological experiment which can identify the positive hits among the entire drug combination library in a parallel and rapid manner. Overall, this microfluidic print-to-screen platform offers a simple, low-cost, high-efficiency solution for high-throughput large-scale combinatorial screening and can be applicable for various emerging applications in drug cocktail discovery.

UR - http://www.scopus.com/inward/record.url?scp=84944937928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944937928&partnerID=8YFLogxK

U2 - 10.1021/acs.analchem.5b00826

DO - 10.1021/acs.analchem.5b00826

M3 - Article

C2 - 26334956

AN - SCOPUS:84944937928

VL - 87

SP - 10166

EP - 10171

JO - Analytical Chemistry

JF - Analytical Chemistry

SN - 0003-2700

IS - 20

ER -